

Project Partners:

1. LEITAT
2. Bar Ilan University
3. Pluristem Therapeutics
4. University Medical Center of Johannes Gutenberg University Mainz
5. MJR PharmJet,
6. BET Solutions
7. National Centre for Scientific Research "Demokritos"
8. Vall d'Hebron Research Institute
9. Vivotecnica Research
10. RIVM
11. Asphalion
12. Cambridge Nanomaterials Technology

nTRACK

CALL: H2020-NMBP-15

Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration

Start date of the project: 01/10/2017

Duration 48 months

D7.4 Dissemination Event I Report

WP	7	Name of the WP: Exploitation strategy and dissemination			
Dissemination level ¹	PU		Due delivery date	31 October 2019	
Nature ²	R		Actual delivery date	04 November 2019	

Lead beneficiary	CNT
Contributing beneficiaries	All partners

Version	Date	Author	Partner	Email	Comments ³
V1.1	30/10/2019	Mónica Spreadbury	CNT	Monica.spreadbury@cnt-ltd.co.uk	First version with initial information input
V1.2	31/10/2019	Mónica Spreadbury Dr Jelena Aleksic Dr Bojan Boskovic	CNT	Bojan.Boskovic@cnt-ltd.co.uk	Input of information, Internal review and approval

¹ Dissemination level: **PU** = Public, **PP** = Restricted to other programme participants (including the JU), **RE** = Restricted to a group specified by the consortium (including the JU), **CO** = Confidential, only for members of the consortium (including the JU)

² Nature of the deliverable: **R** = Report, **P** = Prototype, **D** = Demonstrator, **O** = Other

³ Creation, modification, final version for evaluation, revised version following evaluation, final

Deliverable abstract

The Deliverable D7.4 is a public event of the nTRACK project, delivered by CNT as part of the task T7.5 Dissemination Plan and Activities. The first Open Day Workshop, as stipulated in the Grant Agreement, took place in Cambridge, UK, on the 30th October 2019, following the M24 Meeting held the previous day. The venue selected was Trinity Hall college, chosen due to its central location and good auditorium room for the meeting. This first workshop focused on the field of nanotechnologies and clinical cell therapy.

This document describes all activities and materials that have been prepared and carried out in advance and during the Open Day, as well as a summary of the event itself.

Table of Content

1. Introduction.....	4
2. Open Day Agenda.....	9
2.1 Guest Speakers.....	9
3. External Participating Organisations	10
4. Annexes.....	14
4.1 List of registered participants, including project partners and guests	14
4.2 Participants interest in project	16
4.3 Photos event & exhibition	17
4.3.1 nTRACK Open Day Workshop presentations photos	17
4.3.2 Project exhibition area photos	19
4.3.3 nTRACK Open Day Workshop – audience and discussion photos.....	20
4.4 Participants attendance sheet	22

1. Introduction

The nTRACK Open Day Workshop was organised by Cambridge Nanomaterials Technology Ltd. (CNT), this was the first opportunity for nTRACK partners to inform a wider audience outside of the project, about the project activities as well as introduce their own activities.

Trinity Hall college in Cambridge was selected as the venue to host the M24 Project Meeting and Open Day Workshop, due to its attractive location and their excellent rooms for both meetings.

The nTRACK Open Day meeting took place at the Lecture Theatre with a small exhibition from the Project Partners, held at the back of the room. Coffee breaks and lunch were served at the Terrace Room outside the Lecture Theatre, with convenient seating places for discussions.



CNT prepared a series of documents ahead of the meeting:

- ✓ 2 types of registration forms, one for nTRACK Partners only (requesting details about their presentation or exhibition needs) and another one for external contacts
- ✓ 2 types of travel and accommodation document. One for nTRACK partners with details on the M24 and Open Day venue meetings, another one for external contacts, with details on the Open Day venue only.
- ✓ An Announcement which was published in the project website and updated regularly
- ✓ A Preliminary Agenda with participating organisations
- ✓ A Final Agenda with delegates profiles

Fig 1 Registration form and Travel & Accommodation document for nTRACK Partners

The figure shows two documents side-by-side. The left document is a 'Registration Form' for the n-TRACK Open Day 2019 Workshop, dated 30th October 2019. It includes fields for Name, Organisation, Address, and a section for 'Your interest in n-TRACK'. The right document is an 'Accommodation and Travel Information' sheet for the same event. It provides details about the location (Trinity Hall, Cambridge), date (30th October 2019), and lists various sponsors and partners at the bottom.

Fig 2 Registration form and Travel & Accommodation document for external delegates

The figure displays three versions of an announcement for the n-TRACK Open Day 2019 Workshop. The leftmost version is a full-page announcement with a header, main text, and logos of partners like LEITAT, ASPHALION, and others. The middle version is a smaller, more concise announcement. The rightmost version is a flyer-style announcement featuring a map of the Trinity Hall location and a list of topics to be discussed during the event.

Fig 3 Announcement for the Open Day

The announcement prepared by CNT for the nTRACK Open Day was published on the Project website, administrated by LEITAT, where the registration form and agenda were also made available to download. The Announcement was updated regularly, with information on the new day organisations who had registered their participation.



Fig 4 Announcement published on the project website

An announcement of the event was also placed by Dr Jelena Aleksic (Senior Innovation Manager at CNT) on LinkedIn page, Stem Cell Group page and Twitter. This announcement was shared by many nTRACK Partners.




Fig 5 Announcement published LinkedIn






Fig 6 Announcement published in Twitter






Fig 7 Announcement shared in social media by several nTRACK Partners

An extensive mapping of the relevant stakeholders was conducted by CNT, including researchers in Industry, Academia, Research Institutes, Hospitals and relevant EU Projects. Individual email invitations were sent to mapped stakeholders, related to participation to the nTRACK Open Day. In addition to mapped stakeholders, relevant CNT contacts were also invited by individual addressed emails. The response was very positive. There were 23 external delegates who registered to the Open Day. List of all delegates, including external participants are in the annex at the end of this document (*annex 4.1*). Scanned of the document with signature of participants is also included in the *annex 4.4*.

Key speakers were identified from the mapping exercise and invited to give guests presentations at the Open Day. Seven guest speakers presented at the meeting.

Follow-up emails with registration forms, were sent to those who expressed interest in participating in the meeting. This document collected also information about interest in the project, responses from the external participants are presented in the *annex 4.2*. A travel and accommodation document with detailed information on the logistics of the meeting, was sent to everyone who registered to the event.

A preliminary agenda with participating organisations was prepared and circulated to all nTRACK Partners prior to be sent it to all participants. This agenda was updated regularly, as new participants and speakers joined. This agenda was also available to download through the project website. A final agenda which included a photo and short profile of all delegates, was printed and distributed on the day, to all attendees.

Photos from the nTRACK Open Day Workshop, including photos from the project exhibition area are included in the *annex 4.3*.




Fig 8 Preliminary Agenda

A final agenda was prepared and delivered to those who attended the Open Day. This agenda included profiles of all delegates and participating organisations.



Fig 9 Final Agenda with Delegates

2. Open Day Agenda

09:00 *Arrival and registration*

09:30 **Welcome and nTRACK Open Day Introduction**

Bojan Boskovic, Managing Director, Cambridge Nanomaterials Technology Ltd (CNT), UK
nTRACK Open Day 2019 Organiser

Jelena Aleksic, Senior Innovation Manager, Cambridge Nanomaterials Technology Ltd (CNT), UK
nTRACK Open Day 2019 Organiser
nTRACK Exploitation Manager

Marc Masa, nTRACK Project Coordinator, LEITAT, Spain

09:50 **Overview of the nTRACK Project**

Marc Masa, Project Coordinator, LEITAT, Spain

10:20 **Nazende Günday Türeli**, MJR PharmJet, Germany

Title: Nano-/microparticles Production at MJR PharmJet and Role in the nTRACK Project

10:50 *Coffee break & exhibition*

11:20 **Margriet Park**, National Institute of Public Health and the Environment (RIVM), Netherlands

Title: Role of RIVM in Aligning Policies and Innovations (Regulatory Agility)

11:45 **Marta Rayo Lunar**, Asphalion, Spain

Title: Role of Asphalion in Regulatory Development of Innovative Products: nTRACK Case

12:10 **Panagiotis Papadimitroulas, and Sophia Sarpaki**, BIOEMTECH, Greece

Title: BIOEMTECH's In-vivo Imaging Approach and the Use of Computational Models in nTRACK Project

12:40 **José Raul Herance**, Vall d'Hebron Research Institute, Spain

Title: Introduction of Vall d'Hebron Research Institute and Role in the nTRACK Project

13:00 *Lunch & exhibition*

2.1 Guest Speakers

14:00 **Mary Murphy**, Senior Lecturer in Regenerative Medicine; Principal Investigator Orthobiology Regenerative Medicine Institute, National University of Ireland, Galway, Ireland

Title: Autostem Project - The development of a Fully Automated Platform for the Manufacture of Stem Cells for Cell Therapies

14:20 Giovanni Giuseppe Giobbe, University College of London - Great Ormond Street Institute of Child Health, UK

Title: Extracellular Matrix Hydrogel Derived from Decellularized Tissues Enables Endodermal Organoid Culture

14:50 Martin Leahy, Scientific Director, National Biophotonics and Imaging Platform Ireland, National University of Ireland, Galway, Ireland

Title: NanoSTARS Imaging for STEM Cell Therapy for Arthritic Joints- Starstem Project.

15:20 *Coffee break & exhibition*

15:40 Judit Morla, Postdoctoral Research Fellow of the Marie Curie Cofund Programme 'TecnioSpringPlus', Molecular Nanoscience and Organic Materials Group (NANOMOL), Institute of Materials Science of Barcelona, ICMAB-CSIC, Spain

Title: Fluorescent Organic Nanoparticles and Their Use as Bioimaging Probes

16:00 Yaoyao Chen, Senior Scientist, STEMCELL Technologies UK Ltd, UK

Title: Robust and Efficient Tools for Pluripotent Stem Cell and Organoid Research

16:20 Pavel Abdulkin, Head of Business Development (Particle Engineering & Microfluidics) at Blacktrace Holdings Ltd - Dolomite Microfluidics, Particle Works UK

Title: Nanoparticle Production Scale-up

16:40 Ingrid Simonic, Deputy Director at Medical Genetics Laboratories Cambridge University Hospital, UK

Title: Chromosomal abnormalities in PSCs by G-banding and AGH

17:00 *Closing remarks*

3. External Participating Organisations



STEMCELL Technologies Inc.
www.stemcell.com

STEMCELL Technologies Inc. is a biotechnology company that develops specialty cell culture media, cell isolation systems and accessory products for life science research. Driven by science and a passion for quality, STEMCELL supports the advancement of scientific research around the world with our catalogue of more than 2000 cell biology research tools.



Regenerative Medicine Institute (REMEDI)
NUI Galway
www.nuigalway.ie/remedi

The **Regenerative Medicine Institute (REMEDI)** is a world-class biomedical research centre focusing on gene therapy and stem cell research.

In state-of-the-art facilities, researchers at REMEDI work together to combine the technologies of gene therapy and adult stem cell therapy with the aim of regeneration and repair of tissues. The unique feature of the research carried out at REMEDI is the novel integration of both therapies in a complementary research and development programme.

Based in the **National University of Ireland, Galway**, REMEDI was established in 2003 through a Science Foundation Ireland (SFI) Centre for Science Engineering and Technology (CSET) award, and industry funding. The institute is located at the National Centre for Biomedical Engineering Science and incorporates the National Cell and Gene Vector Laboratory, a GMP grade vector and cell production facility.

REMEDI is a partnership involving scientists, clinicians, and engineers in academic centres and in industry. It is a unique cluster of talented and committed individuals who share a vision in developing new and successful treatment options for patients.




Novo Nordisk A/C
www.novonordisk.com

At **Novo Nordisk**, we are driving change to defeat diabetes and other serious chronic diseases.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries.



Wellcome - MRC Cambridge Stem Cell Institute
University of Cambridge
www.stemcells.cam.ac.uk

The **Wellcome - MRC Cambridge Stem Cell Institute** at the **University of Cambridge** is a research centre for the nature and potential medical uses of stem cells. It is located on the Cambridge Biomedical Campus in Cambridge, England. The Cambridge Stem Cell Institute is a world-leading centre for stem cell research with a mission to transform human health through a deep understanding of stem cell biology. Our scientists study stem cell behaviour, both normal and pathological, and use their findings to improve the prevention, diagnosis and treatment of diseases.

Our Institute consists of 29 outstanding research groups, working across three key research themes: Stem Cell States, Stem Cells in Disease and Stem Cells & Therapeutics.

In 2019, our investigators will come together in a purpose-built new building on the Cambridge Biomedical Campus. The new Institute will bring together scientists from multiple disciplines, operating across many tissues and at multiple scales. This unique set up will allow commonalities and differences in stem cell biology to be explored in a cohesive and inter-disciplinary manner.



Cell and Gene Therapy Catapult

ct.catapult.org.uk

The **Cell and Gene Therapy Catapult** is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. Supported by Innovate UK, our mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies. We are based on the 12th floor of Guy's Hospital in central London, with over 170 cell and gene therapy experts, state-of-the art development and viral vector laboratories. We have also built a £55m large-scale GMP manufacturing centre to help bring cell and gene therapies to market in the UK and internationally.



UCL Great Ormond Street Institute of Child Health

[www. ucl.ac.uk/child-health](http://www.ucl.ac.uk/child-health)

The **UCL Great Ormond Street Institute of Child Health** (GOS ICH) which, together with its clinical partner Great Ormond Street Hospital for Children (GOSH), forms the largest concentration of children's health research in Europe.

The inspirational mission of the UCL Great Ormond Street Institute of Child Health is to: "improve the health and well-being of children, and the adults they will become, through world-class research, education and public engagement".



The Institute of Materials Science of Barcelona (ICMAB-CSIC)

icmab.est



Molecular Nanoscience and Organic Materials Group (NANOMOL)

projects.icmab.es/nanomol

The **Institute of Materials Science of Barcelona (ICMAB-CSIC)** is a multidisciplinary research center focused on cutting-edge research in functional advanced materials in the fields of energy, electronics, nanomedicine and application fields yet to imagine. In 2018, the total personnel of the institute were 332 people.

NANOMOL is a research group with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties. We continuously generate new knowledge in our basic and applied research projects regarding the micro and nano structuring of molecular materials. We offer this knowledge to improve the properties of products manufactured in diverse sectors, such as chemicals, pharmaceuticals and electronics, thereby contributing to increasing their added value. As a group, we are actively involved in implementing nanotechnology and sustainable and economically efficient technologies for preparing advanced functional molecular materials.



School of Life and Medical Sciences University College London

www.ucl.ac.uk/translational-research

The **Translational Research Office** (TRO) facilitates the translation of **UCL**'s emerging research into therapies, techniques and medical products. Translational research is the process whereby ideas and discoveries from emerging research projects are translated into products of therapeutic value for human patient benefit. Where discoveries in "basic science" improve our understanding of a disease, the aim of translational research is to move basic science into practice, to improve human health through the development of drugs, therapies, techniques and medical devices.



Blacktrace Holdings Ltd

www.blacktrace.com

Dolomite

www.dolomite-microfluidics.com

Dolomite is the world leader in design and manufacture of high quality innovative microfluidic products.

Based in Royston (near Cambridge), UK, Dolomite is part of the **Blacktrace group** of companies, a world leader in Productizing Science™. We have offices in the USA, Japan, India and Brazil and worldwide distributors offering technical assistance and support. Productizing Science™ means creating marketable and commercially successful products from scientific discovery, and Dolomite excels in commercialising microfluidic products which exceed expectations.

Since forming in 2005, Dolomite has grown year on year and now has many thousands of customers in over 50 countries. Our customers include a wide range of major academic institutes, biotechs, start-ups, pharmaceutical companies, manufacturers, petrochemical companies, government institutes and virtually any company or organisation that involves science.



Johnson Matthey

matthey.com

Johnson Matthey (LSE: JMAT) is a British multinational speciality chemicals and sustainable technologies company headquartered in the United Kingdom.

It has five global divisions, each of one focussed on the development of high value added, high technology products and services. With 200-year commitment to innovation keeps them at the forefront of technological breakthroughs that make the world a better place.

Enabled by their science, manufacturers across many industries, including automotive, petrochemicals and pharmaceuticals, apply their innovations to improve the function, performance and safety of their products at a lower environmental cost.



Centre for Business Innovation Limited (CfBI)

www.cfbi.co.uk

The **Centre for Business Innovation Limited (CfBI)** is a new type of service organisation, headquartered in Cambridge, UK. We create and facilitate communities whose participants work together in a trusting environment, towards common goals or under a brand which reflects their values and beliefs in order to 'do more with less' in the spirit of Open Innovation. CfBI's team have been refining the formula for over fifteen years to help members all over the world to get optimum benefit.



**Cambridge
University Hospitals
NHS Foundation Trust**

Cambridge University Hospitals NHS Foundation Trust

<https://www.cuh.nhs.uk>

Cambridge University Hospitals is one of the largest and most renowned NHS Trusts in the country. In addition to delivering care through Addenbrooke's and The Rosie Hospitals, CUH is also a leading national centre for specialist treatment, a government-designated comprehensive biomedical research centre, one of only five academic health science centres in the UK, and a university teaching hospital with a worldwide reputation. The Trust employs around 10,000 people. The East Anglian Medical Genetics Service comprises the genetics laboratories (molecular genetics and cytogenetics) and clinical genetics and together they: Diagnose genetic disorders - in the clinic and using lab tests. Counsel individuals and families - for example offering risk assessments for patients who have a family history of an inherited disorder or familial cancer syndrome, Research the causes of birth defects and genetic diseases. Educate health care professionals about

genetics. The service is provided by an integrated team of doctors, genetic counsellors and laboratory scientists, who are supported by secretarial and administrative staff.



The **Sartorius Group** is a leading international partner of the biopharmaceutical industry and the research sector. We are helping biotech scientists and engineers across the entire globe to develop and manufacture medications from the first idea to production. So more people will have access to better medicine.



Kings College London
www.kcl.ac.uk/scms

The **King's British Heart Foundation (BHF) Centre of Research Excellence** was established through a national competition in April 2008, and was successfully renewed in 2014 and 2019, receiving a total of £21 million funding to date.

The mission of the King's BHF Centre is to improve outcomes for patients with cardiovascular conditions through research-led discovery and innovation.

The Centre brings together a wide range of internationally renowned scientists and clinicians who are focused on basic and applied work that leads to advances in the early diagnosis, prevention and treatment of heart diseases. Our ethos is to stimulate novel cutting-edge research by stimulating and facilitating interactions across disciplines, including those between basic scientists and clinicians.

4. Annexes

4.1 List of registered participants, including project partners and guests

Name	Organisation	Country
Marta Morales	Asphalion, S.L.	Spain
Marta Rayo Lunar	Asphalion, S.L.	Spain
Panagiotis Papadimitroulas	BIOEMTECH	Greece
Sophia Sarpaki	BIOEMTECH	Greece
Bojan Boskovic	Cambridge Nanomaterials Technology Ltd	UK
Jelena Aleksic	Cambridge Nanomaterials Technology Ltd	UK
Monica Spreadbury	Cambridge Nanomaterials Technology Ltd	UK
Anna Williams	Cell and Gene Therapy Catapult	UK
Hanna Milewicz	Cell and Gene Therapy Catapult	UK
Peter Hewkin	Centre for Business Innovation	UK
Pavel Abdulkin	Dolomite Microfluidics - Blacktrace	UK

Valentina Nappo	Dolomite Microfluidics - Blacktrace	UK
Ingrid Simonic	East Anglian Medical Genetics Laboratory Cambridge University Hospital	UK
Judit Morla	Institute of Materials Science of Barcelona (ICBAM-CSIC)	Spain
Virginie Buche	Johnson Matthey	UK
Elisa Duregotti	King's College	UK
Marc Masa	LEITAT	Spain
Izabel Alfany	LEITAT	Spain
Gemma Janer	LEITAT	Spain
Jose Luis Muñoz Gómez	LEITAT	Spain
Pauline Rasera	LEITAT	Spain
Nazende Günday Türeli	MJR PharmJet GmbH	Germany
Martin J. Leahy	National University of Ireland Galway	Ireland
Barbara Fazekas	National University of Ireland Galway	Ireland
Camilla Ingvorsen	Novo Nordisk A/S	Denmark
Rikke Skyggebjerg Bjerring	Novo Nordisk A/S	Denmark
Racheli Ofir	Pluristem Therapeutics	Israel
Mary Murphy	Regenerative Medicine Institute (REMEDI) National University of Ireland Galway	Ireland
Claudette de Vries	RIVM	Netherlands
Ingrid Hegger	RIVM	Netherlands
Richard Wales	Sartorius Corporate Research	UK
Wing Chang	STEMCELL Technologies UK Ltd	UK
Yaoyao Chen	STEMCELL Technologies UK Ltd	UK
Ruth Brennan	STEMCELL Technologies UK Ltd	UK
Asha Recino	UCL	UK
Daniel J. Fullen	UCL	UK
Giovanni Giobbe	University College London – GOS Institute of Child Health	UK
Jennifer Oberlaender	University Medical Center of the Johannes Gutenberg-University of Mainz	Germany
Volker Mailänder	University of Mainz (UMC)	Germany
José Raul Herance	Vall d'Hebron Research Institute (VHIR)	Spain

Osmay Carrasco Sochasckyy	Vivotecnia Research S.L	Spain
Maria Colzani	Wellcome - MRC Cambridge Stem Cell Institute - University of Cambridge	UK
Lay Ping Ong	Wellcome - MRC Cambridge Stem Cell Institute - University of Cambridge	UK



4.2 Participants interest in project

Name	Organisation	Interest regarding nTRACK
Anna Williams	Cell and Gene Therapy Catapult	Interesting in learning about multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration and how this can impact the cell and gene therapy field
Hanna Milewicz	Cell and Gene Therapy Catapult	I am interested in state-of-art imaging technologies for tracking stem cells.
Maria Colzani	Wellcome - MRC Cambridge Stem Cell Institute - University of Cambridge	Potential application of nanomaterial for stem cell tracking in the context of the failing heart.
Lay Ping Ong	Wellcome - MRC Cambridge Stem Cell Institute - University of Cambridge	One of the key challenges in the delivery of stem cells to patients involve a reliable, non-toxic, long-term tracking of their behaviour in vivo (or in patients), together with clinical correlates of improvement in organ function. nTRACK and its potential technology to track the delivery of stem cells is highly aligned with our goal in cardiac regeneration therapy.
Camilla Ingvorsen	Novo Nordisk A/S	Work with histology and imaging in Stem Cell R&D at Novo Nordisk
Rikke Bjerring Skyggebjerg	Novo Nordisk A/S	Tracking of injected cells at various sites and correlations to in vivo efficacy or safety.
Daniel J. Fullen	UCL	I have several projects that would like to use cell tracking technology
Wing Chang	STEMCELL Technologies UK Ltd	The nTRACK consortium is examining important issues in the application of stem cells, thus, I am interested in hearing more about multimodal applications for stem cell therapy.
Yaoyao Chen	STEMCELL Technologies UK Ltd	The nTRACK consortium is examining important issues in the application of stem cells, thus, I am interested in hearing more about multimodal applications for stem cell therapy.
Ruth Brennan	STEMCELL Technologies UK Ltd	Learn about progress of the project.
Giovanni Giobbe	University College London – GOS Institute of Child Health	Guest Speaker from the Horizon 2020 INTENSE project. His work within the INTENS project focuses on the

		development of ECM intestinal gel, for the culture of human organoids.
Barbara Fazekas	National University of Ireland Galway	I am interested in Nanomedicinal approaches that allows tracking (in vivo whole body bio-distribution) various resident or exogenously administered immune cells/stem cells or therapeutic drugs. I am also interested in targeted delivery of exogenously administered, nanoparticle labelled cells and other therapeutic drugs.
Ingrid Simonic	East Anglian Medical Genetics Laboratory Cambridge University Hospital	I am interested in cell manipulation and impact on the genomic integrity of the cells. I am an expert in stem cell quality assessment by G-banding and array CGH
Richard Wales	Sartorius Corporate Research	Interest in novel cell tracking and analysis systems for in-vitro and in-vivo applications
Valentina Nappo	Dolomite Microfluidics	Dolomite has a strong interest in developing new methods for fast nano-particle production to be used as drug vehicle in biomedical applications.

4.3 Photos event & exhibition

4.3.1 nTRACK Open Day Workshop presentations photos

	<p>Welcome and nTRACK Open Day Introduction</p> <p>Bojan Boskovic, Cambridge Nanomaterials Technology Ltd (CNT), UK nTRACK Open Day 2019 Organiser</p> <p>Jelena Aleksic, Cambridge Nanomaterials Technology Ltd (CNT), UK nTRACK Open Day 2019 Organiser nTRACK Exploitation Manager</p> <p>Marc Masa, nTRACK Project Coordinator, LEITAT, Spain</p>
	<p>Overview of the nTRACK Project</p> <p>Marc Masa, Project Coordinator, LEITAT, Spain</p>

	<p>Nazende Günday Türeli, MJR PharmJet, Germany</p>
	<p>Panagiotis Papadimitroulas, BIOEMTECH, Greece</p>
<p>Guest Speakers</p>	
	<p>Mary Murphy, Senior Lecturer in Regenerative Medicine; Principal Investigator Orthobiology Regenerative Medicine Institute, National University of Ireland, Galway, Ireland</p> <p>Title: Autostem Project - The development of a Fully Automated Platform for the Manufacture of Stem Cells for Cell Therapies</p>
	<p>Giovanni Giuseppe Giobbe, University College of London - Great Ormond Street Institute of Child Health, UK</p> <p>Title: Extracellular Matrix Hydrogel Derived from Decellularized Tissues Enables Endodermal Organoid Culture</p>
	<p>Martin Leahy, Scientific Director, National Biophotonics and Imaging Platform Ireland, National University of Ireland, Galway, Ireland</p> <p>Title: NanoSTARS Imaging for STEM Cell Therapy for Arthritic Joints- Starstem Project.</p>



Judit Morla, Postdoctoral Research Fellow of the Marie Curie Cofund Programme 'TecnoSpringPlus', Molecular Nanoscience and Organic Materials Group (NANOMOL), Institute of Materials Science of Barcelona, ICMAB-CSIC, Spain

Title: Fluorescent Organic Nanoparticles and Their Use as Bioimaging Probes

4.3.2 Project exhibition area photos



Asphalion's stand at exhibition



Vivotecnia's exhibit



nTRACK partners' leaflets and Bioemtech banner at exhibition



nTRACK Open Day Registration Desk



CNT banner at exhibition

4.3.3 nTRACK Open Day Workshop – audience and discussion photos





4.4 Participants attendance sheet



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 761031.

n-TRACK Project Open Day 2019

Trinity Hall, Cambridge
30 October 2019

List of participants

Name	Organisation	Signature
Marta Morales	Asphalion, S.L.	
Marta Rayo Lunar	Asphalion, S.L.	
Panagiotis Papadimitroulas	BIOEMTECH	
Sophia Sarpaki	BIOEMTECH	
Bojan Boskovic	Cambridge Nanomaterials Technology Ltd	
Jelena Aleksic	Cambridge Nanomaterials Technology Ltd	
Monica Spreadbury	Cambridge Nanomaterials Technology Ltd	
Anna Williams	Cell and Gene Therapy Catapult	
Hanna Milewicz	Cell and Gene Therapy Catapult	
Peter Hewkin	Centre for Business Innovation	
Pavel Abdulkin	Dolomite Microfluidics - Blacktrace	
Valentina Nappo	Dolomite Microfluidics - Blacktrace	
Ingrid Simonic	East Anglian Medical Genetics Laboratory Cambridge University Hospital	
Judit Morla	Institute of Materials Science of Barcelona (ICBAM-CSIC)	
Virginie Buche	Johnson Matthey	
Elisa Duregotti	King's College London – British Heart Foundation Centre	
Marc Masa	LEITAT	
Izabel Alfany	LEITAT	
Gemma Janer	LEITAT	
Jose Luis Muñoz	LEITAT	
Gómez	LEITAT	
Pauline Rasera	LEITAT	



N-TRACK Project Open Day 2019 – List of participants

Nazende Günday Türeli	MJR PharmJet GmbH	
Martin J. Leahy	National University of Ireland Galway	
Barbara Fazekas	National University of Ireland Galway	
Camilla Ingvorsen	Novo Nordisk A/S	
Rikke Skyggebjerg	Novo Nordisk A/S	
Racheli Ofir	Pluristem Therapeutics	
Mary Murphy	Regenerative Medicine Institute (REMEDI)	
Richard Wales	National University of Ireland Galway	
	Sartorius Corporate Research	
Wing Chang	STEMCELL Technologies UK Ltd	
Yaoyao Chen	STEMCELL Technologies UK Ltd	
Ruth Brennan	STEMCELL Technologies UK Ltd	
Asha Recino	UCL	
Daniel J. Fullen	UCL	
Giovanni Giobbe	University College London – GOS Institute of Child Health	
Jennifer Oberlaender	University Medical Center of the Johannes Gutenberg-University of Mainz	
Volker Mailänder	University of Mainz (UMC)	
José Raul Herance	Vall d'Hebron Research Institute (VHIR)	
Osmar Carrasco	Vivotecnica Research S.L	
Sochasckyy	Wellcome - MRC Cambridge Stem Cell Institute - University of Cambridge	
Maria Colzani	Wellcome - MRC Cambridge Stem Cell Institute - University of Cambridge	
Lay Ping Ong	Wellcome - MRC Cambridge Stem Cell Institute - University of Cambridge	